BioCentury
ARTICLE | Clinical News

Kevetrin thioureidobutyronitrile: Completed Phase I enrollment

November 23, 2015 8:00 AM UTC

Cellceutix completed enrollment of >40 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle. Next half, the c...